# Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria

> **NCT01713725** · PHASE2 · COMPLETED · sponsor: **Clinica Universidad de Navarra, Universidad de Navarra** · enrollment: 20 (actual)

## Conditions studied

- Chronic Urticaria

## Interventions

- **BIOLOGICAL:** Omalizumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01713725
- **Lead sponsor:** Clinica Universidad de Navarra, Universidad de Navarra
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2016-02
- **Final completion:** 2017-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-10-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01713725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01713725, "Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01713725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*